Skip to content
DataLookout
Menu

REFIL-2NCT07695363

Restrictive Fluid Management In Liver Transplantation (REFIL)

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 6 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Nov 2030 to Jun 1, 2031 Show 8 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment increased: 866 → 1364 participants
    • Eligibility criteria shortened, about 16 words
    • Study completion pushed from Nov 2031 to Jun 1, 2032
    • Secondary endpoints: 26 to 25
    • Site details revised at 1 of 4 sites
    • Collaborators: 3 to 4
    • Publications: details revised at 4 of 4 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Number of participants with at least one severe complication up to hospital discharge
Timeframe: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
Number of participants who were transfused at least one unit of red blood cells (RBC) up to hospital discharge
Timeframe: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first

Secondary (25)

Number of participants who were transfused at least one unit of red blood cells (RBC) during surgery
Number of participants who were transfused at least one unit of red blood cells (RBC) during the perioperative period of surgery
Intraoperative blood loss
Number of participants who were transfused at least one unit of any labile blood product up to hospital discharge
7-day quality of recovery
Show 20 moreShow less
Number of participants with a 7-day graft dysfunction
Number of participants with a 7-day acute kidney injury (AKI)
Number of participants with at least one postoperative hemorrhagic complication up to hospital discharge
Number of participants with postoperative acute kidney injury (AKI) up to hospital discharge
Number of participants requiring renal replacement therapy (RRT) up to hospital discharge
Number of participants with at least one postoperative graft complication up to hospital discharge
Number of participants with at least one postoperative infectious complication up to hospital discharge
Number of patients with a postoperative wound dehiscence up to hospital discharge
Number of patients with at least one postoperative pulmonary complication up to hospital discharge
Number of participants with at least one postoperative thromboembolic complication up to hospital discharge
Number of participants with a postoperative ICU readmission up to hospital discharge
Number of days not in an intensive care unit (ICU) at 30 days after surgery (30-day ICU-free days over 30 days)
Number of days without organ support at 30 days after surgery (30-day organ support free days)
Hospital length of stay
Quality of life score
Rate of hospital readmissions
Rate of 1-year graft complications
Rate of 1-year graft survival
Rate of 1-year recipient survival
Costs of the intervention

Arms and interventions

Restrictive group - Low splanchnic blood volume restrictive fluid management strategyExperimental

A phlebotomy (a procedure where the patient's blood is drawn, similar to a blood donation, without fluid replacement) at the start of the surgery combined with fluid restriction (use of vasopressor preferentially to treat hemodynamic instability with tolerance to relative hypovolemia defined as a Pulse Pressure Variation (PPV) or Stroke Volume (SVV) up to 18%). Fluids will be administered to compensate for blood loss and/or treat severe hemodynamic instability. Blood collected by phlebotomy will always be transfused back at the beginning of the reperfusion phase, during which fluid management will be based on goal-directed therapy (GDT) using either PPV or SV, as in the control group.

Liberal group - Optimized cardiac output liberal fluid management strategyActive comparator

Goal-directed therapy (GDT): Patients will receive 250 ml fluid boluses until SV stops increasing by more than 10% or until PPV is below 12%. Fluids will thus be used preferentially to treat hemodynamic instability. Fluids will also be administered to compensate for blood loss and/or treat severe hemodynamic instability.

Procedures: Low splanchnic blood volume restrictive fluid management strategy, Phlebotomy, Optimized cardiac output liberal fluid management strategy

Sites

4 sites in 1 country